- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer2023 | First Faculty of Medicine
- Imunoterapie dostarlimabem u pacientky s recidivujícím karcinomem endometria2023 | First Faculty of Medicine
- Pokročilý endometriální adenokarcinom a imunoterapie2022 | Faculty of Medicine in Pilsen
- Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)2021 | Publication without faculty affiliation